Tianjin Cancer Hospital Initiates Clinical Trial to Evaluate Safety and Efficacy of Lianprocaine Disodium for Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

Strategic Insights -

Tianjin Cancer Hospital has registered a significant clinical trial to study the safety and efficacy of Lianprocaine Disodium in general anesthetic induction for breast cancer patients undergoing neoadjuvant chemotherapy. The trial aims to explore the optimal dosing regimen of Lianprocaine Disodium to minimize risks associated with anesthesia management in this patient population. The study highlights the need for pharmacokinetic and dose-effect data specific to neoadjuvant chemotherapy patients, as existing studies have primarily focused on the general surgical population.

Key Takeaways:

  • The clinical trial, registered with the Chinese Clinical Trial Registry (ChiCTR) as ChiCTR2500105830, aims to evaluate the safety and efficacy of Lianprocaine Disodium in breast cancer patients undergoing neoadjuvant chemotherapy.
  • Neoadjuvant chemotherapy significantly increases the complexity and risk of anesthesia management due to adverse effects on organ function, immune status, and hemodynamics.
  • Lianprocaine Disodium, a water-soluble prodrug of propofol, offers metabolic advantages, reduced injection pain, organ protection potential, and prolonged anti-inflammatory effects.
  • The study aims to provide a reference for clinical anesthesia by exploring the optimal dosing regimen of Lianprocaine Disodium in neoadjuvant chemotherapy patients.
  • The full-text of the clinical trial can be found on the Chinese Clinical Trial Registry website.

Statistics:

  • Registration number of the clinical trial: ChiCTR2500105830
  • Study type: Interventional
  • Objectives of the study: To explore the safety and efficacy of different doses of Lianprocaine Disodium during the induction phase of general anesthesia in neoadjuvant chemotherapy patients.
  • Population of interest: Breast cancer patients undergoing neoadjuvant chemotherapy.

Sources:

  • Chinese Clinical Trial Registry (ChiCTR)
  • Contify.com